Topics

Progress of CAR-T Therapy for GBM

Cancer Immunotherapy Tumor Microenvironment Neurodegeneration Cellular Stress

Glioblastoma is a compelling but difficult target for CAR-T therapy. The disease is locally invasive, molecularly heterogeneous, and almost universally recurrent after surgery, radiation, and temozolomide. CAR programs have targeted EGFRvIII, IL13Rα2, HER2, and B7-H3, providing proof that engineered T cells can be manufactured, delivered to the central nervous system, and recognize glioma-associated antigens. Durable responses have remained uncommon, and no single antigen covers every malignant cell. Progress therefore depends on integrating target selection with route of delivery, spatial tumor biology, and resistance to the suppressive brain tumor microenvironment. The field has moved from simple single-target feasibility toward multispecific, locally delivered, and microenvironment-responsive cell designs The blood-brain barrier is not absolute in glioblastoma, but vascular abnormalities and treatment effects make cell access spatially inconsistent[1][2][3].

CAR-T cells recognize surface antigen independently of major histocompatibility complex, then activate cytotoxicity through CD3ζ and a costimulatory domain. In glioblastoma, antigen heterogeneity permits negative clones to survive, while antigen expression can change after treatment. The tumor also contains suppressive myeloid cells, regulatory T cells, inhibitory cytokines, hypoxia, nutrient stress, and extracellular matrix that restrict infiltration and function. Systemic delivery must overcome sequestration and trafficking barriers, whereas intracavitary or intraventricular administration places cells closer to disease but may not uniformly reach infiltrative foci. Repeated antigen exposure and checkpoint signaling promote exhaustion, and corticosteroids used for cerebral edema can further suppress therapeutic lymphocytes Loss of one antigen after selective pressure can leave a histologically similar tumor that is functionally invisible to the infused cells[1][3].

Clinical strategies include regional infusion, repeated dosing, tandem or pooled receptors, and CAR-T cells engineered to secrete cytokines or resist TGF-β and checkpoint inhibition. Targeting IL13Rα2 or EGFRvIII can spare much normal brain because expression is enriched in tumor, but heterogeneous or changing density still demands careful assessment. Multispecific recognition may broaden coverage, while synNotch or logic-gated systems can use one tumor cue to induce a second recognition program. Combinations with radiation, oncolytic viruses, checkpoint inhibitors, or myeloid-directed therapy may improve antigen release and local inflammation. Neuroinflammation, edema, and on-target recognition in normal tissue remain central safety concerns and require controllable dosing and rapid intervention pathways Because edema and inflammation share symptoms with progression, response assessment must integrate imaging, neurologic status, and treatment timing[1][2].

Future trials should map antigen expression across regions and time, because one biopsy cannot represent an infiltrative glioblastoma. Cerebrospinal fluid and tumor sampling can track CAR persistence, cytokines, antigen loss, and immune remodeling after regional treatment. Models should preserve human myeloid cells and brain matrix rather than evaluating tumor killing alone. Steroid exposure, lymphocyte counts, prior radiation, and delivery route need standardized reporting. Engineering must also remain manufacturable and include safety switches when autonomous cytokine activity is introduced. CAR-T therapy for glioblastoma has established biologic feasibility; its next advance will require adaptive target coverage and cells that can patrol the central nervous system without triggering uncontrolled inflammation or losing function in the tumor niche Collaboration across neurosurgery, neuro-oncology, immunology, and cell manufacturing is necessary for repeated regional administration and safe monitoring[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-11109 Resatorvid
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases.
Toll-like Receptor (TLR)   TNF Receptor   Interleukin Related   Autophagy  
Prostate Cancer   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
536
HY-50895 Gefitinib
Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
EGFR   Autophagy   Apoptosis  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Lipid Metabolism   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Metastatic Breast Cancer   SARS-CoV-2 Infection  
222
HY-15772 Osimertinib
Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
EGFR  
Lung Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Glucose Metabolism   SARS-CoV-2 Infection   Hepatitis C Virus Infection   Obesity  
208
HY-B2176 ATP
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.

Source: widespread

Endogenous Metabolite   NOD-like Receptor (NLR)   Interleukin Related   Bacterial  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
178
HY-B0240 Disulfiram
Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram, a copper ion carrier, with Cu2+ increases intracellular ROS levels and induces cuproptosis.
Aldehyde Dehydrogenase (ALDH)   Interleukin Related   Pyroptosis   Apoptosis   Cuproptosis  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Autoimmune Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
161
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Interleukin Related   NO Synthase   Heme Oxygenase (HO)  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Depression   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
147
HY-50896 Erlotinib
Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions.
EGFR   OAT   ERK   GSK-3   β-catenin  
Gastric Cancer   Pancreatic Cancer   Renal Disease   Non-Small Cell Lung Cancer   Lung Adenocarcinoma  
147
HY-10261 Afatinib
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.
EGFR   Autophagy   Apoptosis   c-Met/HGFR   Akt   p38 MAPK  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Hepatitis C Virus Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
113
HY-50898 Lapatinib
Lapatinib (GW572016) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
EGFR   Autophagy   Ferroptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   HER-2 Positive Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Hepatitis C Virus Infection   Obesity  
100
HY-14596 Genistein
Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.
EGFR   Autophagy   Apoptosis   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Lung Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Digestive System Inflammation   SARS-CoV-2 Infection   Hepatitis C Virus Infection   Obesity  
94
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-14519 Methotrexate
Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
Antifolate   Dihydrofolate reductase (DHFR)   NO Synthase   COX   Interleukin Related  
Breast Cancer   Arthritis   Systemic Lupus Erythematosus   Psoriasis   Lung Fibrosis  
87
HY-14590 Kaempferol
Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer.
Estrogen Receptor/ERR   Autophagy   Mitophagy   Apoptosis   HIV   Parasite   Endogenous Metabolite  
Digestive System Disease   Lung Cancer   Breast Cancer   Ovarian Cancer   Viral Infection   Parasitic Infection   Digestive System Inflammation   Glucose Metabolism  
85
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-107202 Polyinosinic-polycytidylic acid
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
RIG-I-like receptor (RLR)   Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Digestive System Disease   Prostate Cancer   Pain   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
73
HY-P9907 Trastuzumab
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)

Species: Human

Radionuclide-Drug Conjugates (RDCs)   EGFR   ADC Antibodies  
Non-Small Cell Lung Cancer   Luminal Breast Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
71
HY-108841 Raleukin
Raleukin (Kineret) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction.

Species: Human

Interleukin Related  
Metastatic Breast Cancer   SARS-CoV-2 Infection   Rheumatoid Arthritis  
57
HY-P9905 Cetuximab
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.

Species: Human

Radionuclide-Drug Conjugates (RDCs)   EGFR  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
57
HY-B1081A Oxidopamine hydrobromide
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome.
Dopamine Receptor   Autophagy   Mitophagy   COX   PGE synthase   Interleukin Related   p38 MAPK   Apoptosis   Caspase  
Breast Cancer   Parkinson's Disease  
50
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-138298 Trastuzumab deruxtecan (solution)
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
Antibody-Drug Conjugates (ADCs)   EGFR  
Breast Cancer   Gastric Cancer  
12
HY-138298A Trastuzumab deruxtecan
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
Antibody-Drug Conjugates (ADCs)   EGFR  
Breast Cancer  
12
HY-P9926 Dupilumab
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease   Breast Cancer   Non-Small Cell Lung Cancer   Staphylococcus Aureus Infection  
9
HY-N3007 Naringenin chalcone
Naringenin chalcone is an orally active intermediate in flavonol biosynthesis. Naringenin chalcone induces Apoptosis. Naringenin chalcone inhibits the production of MCP-1 and NO. Naringenin chalcone exhibits anticancer activity against glioblastoma. Naringenin chalcone has anti-inflammatory and anti-allergic properties.
Drug Intermediate   Apoptosis   NO Synthase  
Neurological, Eye or Ear Disease   Digestive System Disease   Glioma   Digestive System Inflammation   Glucose Metabolism  
8
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-W250978 Ovalbumins
Ovalbumins are the major proteins in egg white. Ovalbumins act as an allergen and inducer, and can be applied to mouse models of allergic diseases. Ovalbumins can induce allergic rhinitis in mice via sensitization and nasal challenge. Ovalbumins can be used to establish asthma models.
Ovalbumin, low endotoxin (HY-W250978A) is recommended for model establishment.
Interleukin Related   IFNAR  
Allergic Asthma   Allergic Rhinitis  
6
HY-B1180 Vinburnine
Vinburnine ((-)-Eburnamonine; (-)-Vincamone) is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine can be used in the research of diseases such as melanoma.
Apoptosis   p38 MAPK  
Melanoma  
3
HY-N0610A Cinnamic acid
Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
Endogenous Metabolite  
Lung Cancer   Prostate Cancer   Melanoma   Glioblastoma  
3
HY-P99762 Obrindatamab
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer.

Species: Human

CD3  
Non-Small Cell Lung Cancer  
2
HY-B1773A Sodium propionate
Sodium propionate is an orally active short-chain fatty acid. Sodium propionate can be produced by intestinal bacteria from the metabolism of dietary fiber. Sodium propionate increases PPAR-γ, inhibits NF-κB activation, and reduces COX-2 expression and NO production. Sodium propionate also induces Apoptosis and Autophagy. Sodium propionate reduces HSV-1-induced keratitis. Sodium propionate has anticancer effects against glioblastoma. Sodium propionate exhibits neuroprotective, antioxidant, and anti-inflammatory activities. Sodium propionate can be used in the research of spinal cord injury and Alzheimer's disease.
Environmental Pollutants   Bacterial   PPAR   NO Synthase   Endogenous Metabolite   HSV   COX   Apoptosis   Autophagy   NF-κB  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Bacterial Infection   Depression   Pain   Digestive System Inflammation   Alzheimer's Disease   Obesity   Rheumatoid Arthritis  
2
HY-P99496 Cendakimab
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis).

Species: Human

Interleukin Related  
Inflammation or Immune System Disease  
1
HY-B1152 Piperacetazine
Piperacetazine is an orally active dopamine receptor antagonist and phenothiazine antipsychotic. Piperacetazine can directly bind to the PAX3::FOXO1 fusion protein and inhibit its transcriptional activity. Piperacetazine also exhibits antitumor activity with an IC50 of 7.627 μM against PANC-1 cells. Piperacetazine can be used for the research of diseases such as schizophrenia and pancreatic cancer and other tumors.
Dopamine Receptor   CD276/B7-H3   FOXO  
Pancreatic Cancer   Schizophrenia   Digestive System Inflammation  
1
HY-P99101 Vobramitamab
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma.

Species: Human

ADC Antibodies  
Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P99242 Alsevalimab
Alsevalimab is a humanized afucosylated IgG1 monoclonal antibody directed against B7-H4. Alsevalimab can be used for the research of advanced solid tumors.

Species: Human

CD276/B7-H3  
Cancer  
1
HY-P99367 Ifinatamab
Ifinatamab is monoclonal immunoglobulin G1-kappa with anti-human B7 homolog 3 protein (Human B7-H3). Ifinatamab is a glycoforme α immunomodulateur.

Species: Human

CD276/B7-H3  
Cancer   Inflammation or Immune System Disease  
1
HY-P9966 Enoblituzumab
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators.

Species: Human

CD276/B7-H3  
Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P7639 CD276/B7-H3 Protein, Mouse (HEK293, His)
CD276/B7-H3 Protein, Mouse (HEK293, His) is induced upon T cell activation. B7-H3 selectively increases the production of IFN-γ.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CAR-T Related Proteins CD Antigens Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins B7-H3 B7-H3/CD276

1
HY-B0114S1 Oxcarbazepine-d4-1
Oxcarbazepine-d4-1 is deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker. Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines. Anti-cancer and anticonvulsant effects.
Isotope-Labeled Compounds   Sodium Channel   Apoptosis  
Cancer   Neurological, Eye or Ear Disease  
/
HY-149696 IR-Crizotinib
IR-Crizotinib is a NF-κB-inducing kinase (NIK) inhibitor that crosses the blood-brain barrier and fluorescently localizes intracranial glioblastoma (GBM) in mice (IC50=3.381 μM). IR-Crizotinib is conjugated from the near-infrared dye IR-786 and the NF-κB-inducing kinase (NIK) inhibitor Crizotinib. IR-Crizotinib can effectively inhibit the growth and invasion of glioma in vitro and in vivo and can be used in cancer research.
NF-κB  
/
HY-N0610AR Cinnamic acid (Standard)
Cinnamic acid (Standard) is the analytical standard of Cinnamic acid. This product is intended for research and analytical applications. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
Reference Standards   Endogenous Metabolite  
Cancer  
/
HY-P10433 EGFRvIII peptide
EGFRvIII peptide is an EGFRvIII-derived epitope for binding to MHC I molecules. EGFRvIII peptide induces apoptosis, and causes specific immune responses against glioblastoma, especially in combination with Flagellin B.
Apoptosis  
Cancer  
/
HY-B0106S Levetiracetam-d6
Levetiracetam-d6 is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent.
Isotope-Labeled Compounds   DNA Methyltransferase  
Cancer   Neurological, Eye or Ear Disease  
/
HY-P991565 CE-355621
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer.

Species: Human

c-Met/HGFR  
Cancer  
/
HY-D3432 WazaGaY-1
WazaGaY-1 is an aza-BODIPY derivative, functions as a NIR-I/NIR-II fluorescent contrast agent. WazaGaY-1 undergoes internalization into tumor cells predominantly via clathrin-coated pits. WazaGaY-1 can be used for the research of glioblastoma, ovarian carcinoma and melanoma (Ex/Em = 685/820 nm).
Fluorescent Dye  
Ovarian Cancer   Cancer Immunology   Immunotherapy for Melanoma   Glioblastoma  
/
HY-N8835 Cannabisin D
Cannabisin D inhibits proliferation and migration of glioblastoma cells through MAPKs signaling.
p38 MAPK  
Neurological, Eye or Ear Disease  
/
HY-P10255 K90-114TAT
K90-114TAT is an inhibitor for EAG2-Kvβ2 interaction, and exhibits antitumor efficacy against glioblastomas.
Potassium Channel  
Cancer  
/
HY-P4098 SynB1
SynB1 is a cell-penetrating peptide with blood-brain barrier permeability, derived from the antimicrobial peptide Protegrin 1. SynB1 enhances the cellular uptake efficiency and cytoplasmic localization level of conjugated constructs. SynB1 can be used in studies related to rabies and glioblastoma.
Others  
Glioblastoma   Rabies Virus Infection  
/
HY-P3990 Coibamide A
Coibamide A, an N-methyl-stabilized cytotoxic depsipeptide, shows potent antiproliferative activity. Coibamide A induces autophagosome accumulation via an mTOR-independent mechanism. Coibamide A induces apoptosis. Coibamide A inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts.
VEGFR   Autophagy   Apoptosis  
/
HY-123903 Tanshindiol B
Tanshindiol B, a naphthaquinone diterpene, inhibits glioblastoma (GBM) growth by induction of noptosis (NQO1-dependent necrosis).
Quinone Reductase  
Cancer  
/
HY-B0114S2 Oxcarbazepine-d8-1
Oxcarbazepine-d8-1 is a deuterium of Oxcarbazepine. Oxcarbazepine is a sodium channel blocker. Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines. Oxcarbazepine-d8-1 has anti-cancer and anticonvulsant effects.
Sodium Channel   Apoptosis  
Cancer   Neurological, Eye or Ear Disease  
/
HY-P11029 CES
CES (CESPLLSEC) is a homing peptide targeting Synaptosomal associated protein 25 (SNAP25). CES specifically homes in intracranial U87MG and the WT-glioblastoma (GBM) model. CES can be used as a targeting peptide for drug delivery for cancers research.
Others  
Cancer  
/
HY-N15588 Smyrindiol
Smyrindiol is a compound found in Dorstenia turbinate. Smyrindiol exerts anti-inflammatory and antimicrobial activities by inhibiting the secretion of tumor-associated proteases (MMP-2). Smyrindiol can be used in the study of brain tumors such as glioblastoma.
MMP  
Cancer  
/
HY-109127S Berotralstat-d4-1
Berotralstat-d4-1 (BCX7353-d4-1) is the deuterium labeled Berotralstat (HY-109127). Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema.
Isotope-Labeled Compounds   Kallikrein  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-P4115 CooP
CooP is a linear glioblastoma-targeting nonapeptide. CooP binds to the mammary-derived growth inhibitor/fatty acid binding protein 3 (FABP3) in the glioblastoma cells and its associated vasculature. CooP is used for the targeted delivery of chemotherapy and different nanoparticles.
FABP  
Cancer  
/
HY-P1828 EGFRvIII peptide (PEPvIII)
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy.
EGFR  
Cancer  
/
HY-16900G Rolipram (GMP)
Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis.
Phosphodiesterase (PDE)   Epigenetic Reader Domain   Amyloid-β  
Depression   Glioblastoma Multiforme   Alzheimer's Disease   Multiple Sclerosis  
/
HY-P11129 MAGE-A4 (286-294)
MAGE-A4 (286-294) is a polypeptide derived from the 286th to 294th amino acids of the MAGE-A4 protein. MAGE-A4 (286-294) binds HLA-­A*02 with an affinity of 560.08 nM and an IC50 of 8.52 nM. MAGE-A4 (286-294) can be detected in various types of cancers (such as esophageal cancer, lung squamous cell carcinoma, bladder cancer). MAGE-A4 (286-294) can be used to produce CAR-T cells and to develop CAR-T cell therapy.
Others  
Cancer  
/
HY-P991970 REGN3124
REGN3124 is a fully human antibody with binding to EGFRvIII. REGN3124 forms REGN3124-PBD via conjugation to pyrrolobenzodiazepine linker-payload SG-3249. REGN3124 can be used for the research of glioblastoma multiforme.

Species: Human

EGFR  
/
HY-P991573 Anti-EGFR Antibody (D2C7)
Anti-EGFR Antibody (D2C7) is a monoclonal antibody against EGFR. The recombinant immunotoxin D2C7-(scdsFv)-PE38KDEL constructed based on Anti-EGFR Antibody (D2C7) has antineoplastic activity in glioblastoma models.

Species: Human

EGFR  
Cancer  
/
HY-N0610S2 Cinnamic acid-d7
Cinnamic acid-d7 (3-Phenylacrylic acid-d7) is the deuterium labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
Isotope-Labeled Compounds   Endogenous Metabolite   Environmental Pollutants  
Cancer  
/
HY-B0114S3 Oxcarbazepine-d10
Oxcarbazepine-d10 (GP 47680-d10) is deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker. Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines. Anti-cancer and anticonvulsant effects.
Isotope-Labeled Compounds   Sodium Channel   Apoptosis  
Cancer   Neurological, Eye or Ear Disease  
/
HY-B0114S Oxcarbazepine-d4
Oxcarbazepine-d4 (GP 47680-D4) is the deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker. Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines. Anti-cancer and anticonvulsant effects.
Isotope-Labeled Compounds   Sodium Channel   Apoptosis  
Cancer   Neurological, Eye or Ear Disease  
/
HY-N18390 5-Methyltetrahydropteroyltri-L-glutamate
5-Methyltetrahydropteroyltri-L-glutamate is an amino acid derivative. 5-Methyltetrahydropteroyltri-L-glutamate is present in the dried extract of Allium sativum (Hisar Garlic No. 17). 5-Methyltetrahydropteroyltri-L-glutamate participates in the remethylation of homocysteine to methionine via cobalamin-independent methionine synthase. 5-Methyltetrahydropteroyltri-L-glutamate is a biomarker associated with altered one-carbon transfer reactions in glioblastoma. 5-Methyltetrahydropteroyltri-L-glutamate can be used in glioblastoma-related research.
Amino Acid Derivatives  
Glioblastoma  
/
HY-P990340 Anti-B7-H3/CD276 Antibody
Anti-B7-H3/CD276 Antibody is a CHO-expressed human antibody targeting B7-H3/CD276. Anti-B7-H3/CD276 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H3/CD276 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

CD276/B7-H3  
Inflammation or Immune System Disease  
/
HY-N12531 Molephantin
Molephantin is a blood-brain barrier permeable anti-glioblastoma compound. Molephantin induces ROS generation, leading to mitochondrial damage, Mitophagy flux blockage and Apoptosis induction. Molephantin can suppress the PI3K/Akt/mTOR signaling pathway. Molephantin demonstrates antitumor effects against glioblastoma.
Reactive Oxygen Species (ROS)   Mitochondrial Metabolism   Mitophagy   Apoptosis   PI3K   Akt   mTOR  
Glioblastoma  
/
HY-B0106S1 Levetiracetam-d3
Levetiracetam-d3 is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent.
DNA Methyltransferase  
Cancer   Neurological, Eye or Ear Disease  
/
HY-N12535 Tagitinin C
Tagitinin C is a sesquiterpenoid compound isolated from the Tithonia diversifolia. Tagitinin C has anticancer activity and can inhibit the proliferation of human glioblastoma U373 cells with an IC50 of 6.1 μg/mL. Tagitinin C can induce U373 cell death and be used in glioblastoma research.
Others  
Cancer  
/
HY-B1180R Vinburnine (Standard)
Vinburnine ((-)-Eburnamonine; (-)-Vincamone) (Standard) is the analytical standard of Vinburnine (HY-B1180). This product is intended for research and analytical applications. Vinburnine ((-)-Eburnamonine; (-)-Vincamone) phosphate is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine can be used in the research of diseases such as melanoma.
Reference Standards   Apoptosis   p38 MAPK  
Melanoma  
/
HY-P11147 IL13Rα2 D1
IL13Rα2 D1 is an effective IL-13/IL13Rα2 signaling axis inhibitor. IL13Rα2 D1 can inhibit IL-13-induced cell adhesion, migration, invasion, and proliferation. IL13Rα2 D1 can inhibit FAK, Src, AKT, ERK1/2 phosphorylation, and MMP expression. IL13Rα2 D1 can be used for research on cancers such as colorectal cancer.
Interleukin Related   FAK   Src   Akt   ERK   MMP  
Cancer  
/
HY-P4111A Peptide R TFA
Peptide R (TFA) is a synthetic and specific CXCR4 antagonist. Peptide R (TFA) shows outstanding capacities to remodel the tumor stroma. Peptide R (TFA) can be used for solid tumor (glioblastoma, etc.) research.
CXCR  
/
HY-P11326 Ac-FR-AFC TFA
Ac-FR-AFC TFA is a fluorometric substrate for cathepsin L. Ac-FR-AFC TFA can be used for the research of glioblastoma.
Cathepsin   Fluorescent Dye  
Glioblastoma  
/
HY-N0610AS2 Cinnamic acid-13C3
Cinnamic acid-13C3 (3-Phenylacrylic acid-13C3) is the 13C labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
Isotope-Labeled Compounds   Endogenous Metabolite  
/
HY-148775 PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25)
PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) is a biodegradable amphipathic polymeric nanocarrier of poly (lactic-co-glycolic acid)-block-poly (ethylene glycol) (PLGA-PEG-Mal) that allows covalent modification of functional molecules. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) modified with Angiopep-2 can cross the blood-brain barrier and exhibits targeting selectivity for glioblastoma cells. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) can capture tumor-derived protein antigens, and exerts immunomodulatory effects when conjugated with anti-OX40 antibody; when used in combination with A2-CL/Dbait nanoparticles and radiotherapy, it prolongs survival time and reduces tumor volume in glioblastoma mouse models. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) can be used for studies related to bacterial wound infections and glioblastoma.
Biochemical Assay Reagents  
Bacterial Infection   Glioblastoma  
/
HY-P99768 Olinvacimab
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer.

Species: Human

VEGFR  
Triple-Negative Breast Cancer  
/
HY-P991662 AMG-595 Antibody
AMG-595 Antibody is a EGFRvIII targeting antibody. AMG-595 Antibody can be used for synthesis of ADC AMG-595.

Species: Human

EGFR   ADC Antibodies  
Cancer  
/
HY-P991470 Anti-Tenascin C Antibody
Anti-Tenascin C Antibody (Neuradiab antibody) is a human monoclonal antibody (mAb) targeting Tenascin C. Anti-Tenascin C Antibody can be used in Glioblastoma research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-P99715 Losatuxizumab
Losatuxizumab is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFRC271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers.

Species: Human

EGFR  
Cancer  
/
HY-P99948 Etevritamab
Etevritamab (AMG-596) is a bispecific T-cell engager that targets EGFRvIII and CD3. Etevritamab simultaneously binds CD3 on T cells and EGFRvIII on glioblastoma multiforme cells, thereby forming a bridge structure. Etevritamab triggers T-cell activation, proliferation, secretion of cytotoxic substances, and tumor cell lysis. Etevritamab extends overall survival and induces tumor regression in mouse models of glioblastoma multiforme. Etevritamab can be used for research related to glioblastoma.

Species: Human

EGFR   CD3  
Glioblastoma  
/
HY-P1828A EGFRvIII peptide (PEPvIII) TFA
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy.
EGFR  
Cancer  
/
HY-W011927R 4,4'-Sulfonyldiphenol (Standard)
4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone) (Standard) is the analytical standard of 4,4'-Sulfonyldiphenol (HY-W011927). This product is intended for research and analytical applications. 4,4'-Sulfonyldiphenol, a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.
Reference Standards   Estrogen Receptor/ERR   Histone Methyltransferase   Thyroid Hormone Receptor   PI3K   Akt   mTOR   Androgen Receptor   Drug Derivative  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P99306 Modotuximab
Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo.

Species: Human

EGFR  
Cancer  
/
HY-P99223 Tovetumab
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC).

Species: Human

PDGFR  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-N0610AS Cinnamic acid-d6
Cinnamic acid-d6 is the deuterium labeled Cinnamic acid. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
Endogenous Metabolite  
/
HY-P99740 Mirzotamab
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC).

Species: Human

CD276/B7-H3   ADC Antibodies  
Cancer  
/
HY-P990059 Puxitatug
Puxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer.

Species: Human

ADC Antibodies   CD276/B7-H3  
Cancer  
/
HY-P991537 Risvutatug
HS-20093 Antibody (GSK5764227 Antibody) is an antibody targeting B7-H3, which can be used to synthesize the ADC HS-20093. HS-20093 Antibody exhibits anti-tumor activity. HS-20093 Antibody can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors.

Species: Human

ADC Antibodies   CD276/B7-H3  
Cancer  
/
HY-P99806 Pritumumab
Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research.

Species: Human

Others  
Cancer  
/
HY-P99445 Asunercept
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein (hIgG1) targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD).
TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P990279 Anti-Mouse CD276/B7-H3 Antibody (MJ18)
Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived anti-mouse CD276/B7-H3 IgG1 monoclonal antibody. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can inhibit CD276/B7-H3 and induce tumor cell apoptosis. Anti-Mouse CD276/B7-H3 Antibody (MJ18) enhances anti-tumor immune response by reducing immunosuppressive cells and promoting T cell activation. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can be used for research on cancer such as breast cancer and prostate cancer.

Species: Mouse

CD276/B7-H3   Apoptosis   STAT  
Inflammation or Immune System Disease   Breast Cancer   Prostate Cancer  
/
HY-148837 GT19630
GT19630 is an orally active c-Myc PROTAC targeted degrader based on the cereblon E3 ubiquitin ligase, with an IC50 of 1.5 nM against human c-Myc. GT19630 mediates the degradation of MYC, GSPT1, GSPT2, CK1 alpha, N-Myc, B7-H3 and XIAP, and disrupts the MYC-GSPT1 synergistic regulatory feedback loop. GT19630 inhibits cell proliferation, blocks S-phase progression of the cell cycle, promotes cell apoptosis, reduces cell migration capacity, induces integrated stress response, and blocks oxidative phosphorylation by inhibiting the TCA cycle. GT19630 can be used in the research of Myc-driven hematological cancers, small cell lung cancer, breast cancer, TP53-mutant cancers, and venetoclax-resistant cancers.
PROTACs   IAP   Oxidative Phosphorylation   CD276/B7-H3   Eukaryotic Release Factor (eRF)   c-Myc   Casein Kinase   Apoptosis  
Breast Cancer   Blood Disease   Small Cell Lung Cancer  
/
HY-171689 Puxitatug samrotecan
Puxitatug samrotecan (AZD 8205) is an antibody-drug conjugate (ADC) targeting B7-H4, formed by the random conjugation of the Puxitatug (HY-P990059) antibody and AZ14170133 (HY-145399) via interchain cysteine reduction. Puxitatug samrotecan binds to B7-H4 to deliver the payload to B7-H4-expressing cells, inhibits topoisomerase I, and induces cytotoxicity in cancer cells and xenograft models. Puxitatug samrotecan can be used in studies of B7-H4-expressing tumors.
Antibody-Drug Conjugates (ADCs)   Topoisomerase   CD276/B7-H3  
Cancer  
/
HY-P99908 Efineptakin alfa
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4+ and CD8+ cells in both human and mice. Efineptakin alfa can be used for glioblastoma research.
Interleukin Related  
Cancer  
/
HY-P99849 Depatuxizumab
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer.

Species: Human

EGFR  
Cancer  
/
HY-P99157 Omburtamab
Omburtamab (Mab 8H9) is a mouse monoclonal immunoglobulin G1 (IgG1) antibody targeting B7-H3. Omburtamab specifically binds to the glycoprotein antigen B7-H3, which is widely expressed on the surface of tumor cells. As a targeting carrier for recombinant toxins, it delivers PE38 to inhibit cellular protein synthesis and induce cytotoxicity in antigen-expressing cancer cells. Omburtamab can be used in research related to glioma, breast cancer, osteosarcoma and neuroblastoma.

Species: Mouse

CD276/B7-H3  
Musculoskeletal and Skin Disease   Breast Cancer   Glioma   Neuroblastoma   Osteosarcoma  
/
HY-W011927 4,4'-Sulfonyldiphenol
4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone), a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an oally ative estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.
Estrogen Receptor/ERR   Histone Methyltransferase   Thyroid Hormone Receptor   PI3K   Akt   mTOR   Androgen Receptor   Drug Derivative  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease  
/
HY-W087830 L-p-Boronophenylalanine
L-p-Boronophenylalanine is a boron-containing substrate for L-type amino acid transporters (LAT1 and LAT2). L-p-Boronophenylalanine enters tumor cells by competing with natural amino acids for LAT, selectively accumulating boron in cancer cells. L-p-Boronophenylalanine can be used in boron neutron capture therapy (BNCT). When boron-10 captures thermal neutrons, a nuclear reaction occurs, producing high-energy alpha particles and lithium nuclei, which kill cancer cells at close range with little damage to surrounding tissues. L-p-Boronophenylalanine can be used in cancer research, especially glioblastoma and anaplastic astrocytoma.
Biochemical Assay Reagents  
Cancer  
/
HY-P991097 Pumitamig
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.

Species: Human

VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P3371 Ifinatamab deruxtecan
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
Antibody-Drug Conjugates (ADCs)   Topoisomerase   Apoptosis   CD276/B7-H3  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Endometrial Cancer  
/
HY-P75827 IL-13R alpha 2 Protein, Human (HEK293, His)
IL-13R alpha 2 Protein, functioning as a monomer, exhibits high-affinity binding exclusively to interleukin-13 (IL13) without interaction with interleukin-4 (IL4). This binding selectivity indicates a unique role and specificity for IL-13R alpha 2 in mediating cellular responses to IL13, emphasizing its importance in IL13-associated cellular processes. IL-13R alpha 2 Protein, Human (HEK293, His) is the recombinant human-derived IL-13R alpha 2 protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors Receptor Proteins Interleukin & Receptors Cytokine Receptors IL-13 Receptor IL-13Rα2

/
HY-P73929 HER2/CD340 Protein, Mouse (HEK293, His)
The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics. Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability. HER2/CD340 Protein, Mouse (HEK293, His) is the recombinant mouse-derived HER2/CD340 protein, expressed by HEK293 , with C-10*His labeled tag.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors CAR-T Related Proteins CD Antigens Receptor Proteins Enzymes & Regulators EGF Superfamily ErbB2/HER2 Stem Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Receptor Tyrosine Kinases Cytokine Receptors Protein Tyrosine Kinases EGFR/ErbB family

/
HY-P75832 IL-13R alpha 2 Protein, Mouse (HEK293, His)
The IL-13R alpha 2 protein is a high-affinity receptor for interleukin 13 (IL-13) that acts as a decoy receptor and does not induce signaling upon IL-13 binding. Mice lacking this protein exhibit increased serum immunoglobulins, interferon gamma production, and bone marrow macrophage progenitor cell frequencies. IL-13R alpha 2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived IL-13R alpha 2 protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors Receptor Proteins Interleukin & Receptors Cytokine Receptors IL-13 Receptor IL-13Rα2

/
HY-P700880 CD276/B7-H3 Protein, Human (Biotinylated, HEK293, C-His-Avi)
CD276/B7-H3 protein can regulate T cell-mediated immune responses and act as a protective factor for tumor cells by inhibiting natural killer-mediated cell lysis. It also functions as a neuroblastoma cell marker, plays a role in acute and chronic transplant rejection, and modulates lymphocyte activity at mucosal surfaces. CD276/B7-H3 Protein, Human (Biotinylated, HEK293, C-His-Avi) is the recombinant human-derived CD276/B7-H3 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CAR-T Related Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins B7-H3 B7-H3/CD276

/
HY-P70125 CD276/B7-H3 Protein, Cynomolgus (HEK293, His)
CD276/B7-H3 protein can regulate T cell-mediated immune responses and act as a protective factor for tumor cells by inhibiting natural killer-mediated cell lysis. It also functions as a neuroblastoma cell marker, plays a role in acute and chronic transplant rejection, and modulates lymphocyte activity at mucosal surfaces. CD276/B7-H3 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD276/B7-H3 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Cynomolgus; Source: HEK293

Immune Checkpoint Proteins CAR-T Related Proteins CD Antigens Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins B7-H3 B7-H3/CD276

/
HY-P70759 HER2/CD340 Protein, Human (HEK293, Fc)
HER2/CD340 Protein, Human (HEK293, Fc) is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (HEK293, Fc) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors CAR-T Related Proteins CD Antigens Receptor Proteins Enzymes & Regulators EGF Superfamily ErbB2/HER2 Stem Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Receptor Tyrosine Kinases Cytokine Receptors Protein Tyrosine Kinases EGFR/ErbB family

/
HY-P74314 CD276/B7-H3 Protein, Rat (HEK293, His)
CD276/B7-H3 Protein regulates T-cell-mediated immune responses and transplant rejection. It also promotes bone formation, functioning at the bone-immune interface. Additionally, it activates immune responses against tumors, eliminating them through natural killer cells and CD8 T-cells. Its interaction with TREML2 enhances T-cell activation, highlighting its role in immune regulation. CD276/B7-H3 Protein, Rat (HEK293, His) is the recombinant rat-derived CD276/B7-H3 protein, expressed by HEK293 , with C-His labeled tag.

Species: Rat; Source: HEK293

Immune Checkpoint Proteins CAR-T Related Proteins CD Antigens Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins B7-H3 B7-H3/CD276

/
HY-P75805 HER2/CD340 Protein, Cynomolgus (HEK293, His)
Erb-b2 receptor tyrosine kinase 2 is a member of EGFR family. Erb-b2 receptor tyrosine kinase 2 is over-expressed in the tumors of many types of cancers. Erb-b2 receptor tyrosine kinase 2 enables ATP binding and transmembrane receptor protein tyrosine kinase activity. HER2/CD340 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag.

Species: Cynomolgus; Source: HEK293

Cytokines and Growth Factors CAR-T Related Proteins CD Antigens Receptor Proteins Enzymes & Regulators EGF Superfamily ErbB2/HER2 Stem Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Receptor Tyrosine Kinases Cytokine Receptors Protein Tyrosine Kinases EGFR/ErbB family

/
HY-P74895 HER2/CD340 Protein, Rat (HEK293, His)
The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics.Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability.HER2/CD340 Protein, Rat (HEK293, His) is the recombinant rat-derived HER2/CD340 protein, expressed by HEK293 , with C-10*His labeled tag.

Species: Rat; Source: HEK293

Cytokines and Growth Factors CAR-T Related Proteins CD Antigens Receptor Proteins Enzymes & Regulators EGF Superfamily ErbB2/HER2 Stem Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Receptor Tyrosine Kinases Cytokine Receptors Protein Tyrosine Kinases EGFR/ErbB family

/
HY-P78930 CD276/B7-H3 Protein, Human (Biotinylated, HEK293, Fc-Avi)
CD276/B7-H3 protein can regulate T cell-mediated immune responses and act as a protective factor for tumor cells by inhibiting natural killer-mediated cell lysis. It also functions as a neuroblastoma cell marker, plays a role in acute and chronic transplant rejection, and modulates lymphocyte activity at mucosal surfaces. CD276/B7-H3 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived CD276/B7-H3 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CAR-T Related Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins B7-H3 B7-H3/CD276

/
HY-P75830 IL-13R alpha 2 Protein, Mouse (HEK293, Fc)
IL-13R alpha 2 Protein, acting as a monomer, displays a strong binding affinity for interleukin-13 (IL-13). IL-13R alpha 2 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived IL-13R alpha 2 protein, expressed by HEK293 , with C-mFc labeled tag.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors Receptor Proteins Interleukin & Receptors Cytokine Receptors IL-13 Receptor IL-13Rα2

/
HY-P73097 HER2/CD340 Protein, Rat (HEK293)
The HER2/CD340 Protein is a member of the receptor tyrosine kinase family.HER2/CD340 Protein participates in the PI3K/Akt signaling pathway to regulate the differentiation and apoptosis of neural stem cells in the cochlear nucleus.HER2/CD340 Protein is an overexpressed oncogenic factor in bladder cancer that activates the oncogenic signaling pathway, thereby promoting tumor cell survival/proliferation.HER2/CD340 Protein, Rat (HEK293) is the recombinant rat-derived HER2/CD340 protein, expressed by HEK293 , with tag free.

Species: Rat; Source: HEK293

Cytokines and Growth Factors CAR-T Related Proteins CD Antigens Receptor Proteins Enzymes & Regulators EGF Superfamily ErbB2/HER2 Stem Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Receptor Tyrosine Kinases Cytokine Receptors Protein Tyrosine Kinases EGFR/ErbB family

/
HY-P78698 IL-13R alpha 2 Protein, Rhesus macaque (HEK293, His)
IL-13R alpha 2 Protein, functioning as a monomer, exhibits high-affinity binding exclusively to interleukin-13 (IL13) without interaction with interleukin-4 (IL4). This binding selectivity indicates a unique role and specificity for IL-13R alpha 2 in mediating cellular responses to IL13, emphasizing its importance in IL13-associated cellular processes. IL-13R alpha 2 Protein, Rhesus macaque (HEK293, His) is the recombinant Rhesus Macaque-derived IL-13R alpha 2 protein, expressed by HEK293 , with C-His labeled tag. The total length of IL-13R alpha 2 Protein, Rhesus macaque (HEK293, His) is 315 a.a., with molecular weight of 45-55 kDa.

Species: Rhesus Macaque; Source: HEK293

Cytokines and Growth Factors Receptor Proteins Interleukin & Receptors Cytokine Receptors IL-13 Receptor IL-13Rα2

/
HY-P74317 CD276/B7-H3 (4Ig)/B7-H3b Protein, Human (HEK293, hFc)
CD276/B7-H3 protein can regulate T cell-mediated immune responses and act as a protective factor for tumor cells by inhibiting natural killer-mediated cell lysis. It also functions as a neuroblastoma cell marker, plays a role in acute and chronic transplant rejection, and modulates lymphocyte activity at mucosal surfaces. CD276/B7-H3 (4Ig)/B7-H3b Protein, Human (HEK293, hFc) is the recombinant human-derived CD276/B7-H3, expressed by HEK293, with C-hFc labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CAR-T Related Proteins CD Antigens Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins B7-H3 B7-H3/CD276

/
HY-P74897 HER2/CD340 Protein, Canine (HEK293, His)
The HER2/CD340 Protein is a member of the receptor tyrosine kinase family. HER2/CD340 Protein participates in the PI3K/Akt signaling pathway to regulate the differentiation and apoptosis of neural stem cells in the cochlear nucleus. HER2/CD340 Protein is an overexpressed oncogenic factor in bladder cancer that activates the oncogenic signaling pathway, thereby promoting tumor cell survival/proliferation. HER2/CD340 Protein, Canine (HEK293, His) is the recombinant canine-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag.

Species: Canine; Source: HEK293

Cytokines and Growth Factors CAR-T Related Proteins CD Antigens Receptor Proteins Enzymes & Regulators EGF Superfamily ErbB2/HER2 Stem Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Receptor Tyrosine Kinases Cytokine Receptors Protein Tyrosine Kinases EGFR/ErbB family

/
HY-P75829 IL-13R alpha 2 Protein, Human (Biotinylated, HEK293, His)
IL-13R alpha 2 Protein, functioning as a monomer, exhibits high-affinity binding exclusively to interleukin-13 (IL13) without interaction with interleukin-4 (IL4). This binding selectivity indicates a unique role and specificity for IL-13R alpha 2 in mediating cellular responses to IL13, emphasizing its importance in IL13-associated cellular processes. IL-13R alpha 2 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived IL-13R alpha 2 protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors Receptor Proteins Biotinylated Proteins Interleukin & Receptors Cytokine Receptors IL-13 Receptor IL-13Rα2

/
HY-P75831 IL-13R alpha 2 Protein, Mouse (HEK293, His-Fc)
IL-13R alpha 2 Protein, acting as a monomer, displays a strong binding affinity for interleukin-13 (IL-13). IL-13R alpha 2 Protein, Mouse (HEK293, His-Fc) is the recombinant mouse-derived IL-13R alpha 2 protein, expressed by HEK293 , with C-hFc, C-His labeled tag.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors Receptor Proteins Interleukin & Receptors Cytokine Receptors IL-13 Receptor IL-13Rα2

/
HY-P75833 IL-13R alpha 2 Protein, Rat (HEK293, Fc)
IL-13R alpha 2 Protein, functioning as a monomer, exhibits strong affinity for binding to interleukin-13 (IL-13), thereby playing a crucial role in mediating the biological effects of IL-13 and regulating various cellular processes. IL-13R alpha 2 Protein, Rat (HEK293, Fc) is the recombinant rat-derived IL-13R alpha 2 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Rat; Source: HEK293

Cytokines and Growth Factors Receptor Proteins Interleukin & Receptors Cytokine Receptors IL-13 Receptor

/
HY-P76989 IL-13R alpha 2 Protein, Canine (HEK293, Fc)
The IL-13R α2 protein is a receptor for interleukin 13 (IL-13), a signaling molecule involved in immune responses. By binding to IL-13, the IL-13R α2 protein is thought to regulate IL-13-mediated immune responses and may serve as a therapeutic target for diseases associated with IL-13 dysregulation. IL-13R alpha 2 Protein, Canine (HEK293, Fc) is the recombinant canine-derived IL-13R alpha 2 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Canine; Source: HEK293

Cytokines and Growth Factors Receptor Proteins Interleukin & Receptors Cytokine Receptors IL-13 Receptor IL-13Rα2

/
HY-P76990 IL-13R alpha 2 Protein, Canine (HEK293, His)
The IL-13R α2 protein is a receptor for interleukin 13 (IL-13), a signaling molecule involved in immune responses. By binding to IL-13, the IL-13R α2 protein is thought to regulate IL-13-mediated immune responses and may serve as a therapeutic target for diseases associated with IL-13 dysregulation. IL-13R alpha 2 Protein, Canine (HEK293, His) is the recombinant canine-derived IL-13R alpha 2 protein, expressed by HEK293 , with C-His labeled tag.

Species: Canine; Source: HEK293

Cytokines and Growth Factors Receptor Proteins Interleukin & Receptors Cytokine Receptors IL-13 Receptor IL-13Rα2

/
HY-P77538 CD276/B7-H3 (4Ig)/B7-H3b Protein, Human (Biotinylated, HEK293, His)
CD276/B7-H3 protein can regulate T cell-mediated immune responses and act as a protective factor for tumor cells by inhibiting natural killer-mediated cell lysis. It also functions as a neuroblastoma cell marker, plays a role in acute and chronic transplant rejection, and modulates lymphocyte activity at mucosal surfaces. CD276/B7-H3 (4Ig)/B7-H3b Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived CD276/B7-H3 protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CAR-T Related Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins B7-H3 B7-H3/CD276

/
HY-P72626 HER2/CD340 Protein, Rat (His)
The HER2/CD340 protein is a key protein tyrosine kinase that is a component of multiple cell surface receptor complexes and requires coreceptors for ligand binding.Its interaction within the neuregulin-receptor complex depends on neuregulin, and GP30 emerges as a potential ligand.HER2/CD340 Protein, Rat (His) is the recombinant rat-derived HER2/CD340 protein, expressed by E.coli , with C-6*His labeled tag.

Species: Rat; Source: E. coli

Cytokines and Growth Factors CAR-T Related Proteins CD Antigens Receptor Proteins Enzymes & Regulators EGF Superfamily ErbB2/HER2 Stem Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Receptor Tyrosine Kinases Cytokine Receptors Protein Tyrosine Kinases EGFR/ErbB family

/
HY-P73930 HER2/CD340 Protein, Mouse (HEK293, Fc)
The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics. Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability. HER2/CD340 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors CAR-T Related Proteins CD Antigens Receptor Proteins Enzymes & Regulators EGF Superfamily ErbB2/HER2 Stem Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Receptor Tyrosine Kinases Cytokine Receptors Protein Tyrosine Kinases EGFR/ErbB family

/
HY-P75834 IL-13R alpha 2 Protein, Rat (HEK293, His)
IL-13R alpha 2 Protein, functioning as a monomer, exhibits strong affinity for binding to interleukin-13 (IL-13), thereby playing a crucial role in mediating the biological effects of IL-13 and regulating various cellular processes. IL-13R alpha 2 Protein, Rat (HEK293, His) is the recombinant rat-derived IL-13R alpha 2 protein, expressed by HEK293 , with C-His labeled tag.

Species: Rat; Source: HEK293

Cytokines and Growth Factors Receptor Proteins Interleukin & Receptors Cytokine Receptors IL-13 Receptor IL-13Rα2

/
HY-P74315 CD276/B7-H3 Protein, Rat (HEK293, Fc)
CD276/B7-H3 Protein regulates T-cell-mediated immune responses and transplant rejection. It also promotes bone formation, functioning at the bone-immune interface. Additionally, it activates immune responses against tumors, eliminating them through natural killer cells and CD8 T-cells. Its interaction with TREML2 enhances T-cell activation, highlighting its role in immune regulation. CD276/B7-H3 Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD276/B7-H3 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Rat; Source: HEK293

Immune Checkpoint Proteins CAR-T Related Proteins CD Antigens Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins B7-H3 B7-H3/CD276

/
HY-P74896 HER2/CD340 Protein, Rat (HEK293, Fc)
The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics.Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability.HER2/CD340 Protein, Rat (HEK293, Fc) is the recombinant rat-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Rat; Source: HEK293

Cytokines and Growth Factors CAR-T Related Proteins CD Antigens Receptor Proteins Enzymes & Regulators EGF Superfamily ErbB2/HER2 Stem Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Receptor Tyrosine Kinases Cytokine Receptors Protein Tyrosine Kinases EGFR/ErbB family

/
HY-P700448 CD276/B7-H3 (4Ig)/B7-H3b Protein, Human (217a.a, HEK293, Myc-hFc)
CD276/B7-H3 protein can regulate T cell-mediated immune responses and act as a protective factor for tumor cells by inhibiting natural killer-mediated cell lysis. It also functions as a neuroblastoma cell marker, plays a role in acute and chronic transplant rejection, and modulates lymphocyte activity at mucosal surfaces. CD276/B7-H3 (4Ig)/B7-H3b Protein, Human (217a.a, HEK293, Myc-hFc) is the recombinant human-derived CD276/B7-H3 protein, expressed by HEK293 , with C-Myc, C-hFc labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CAR-T Related Proteins CD Antigens Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins B7-H3 B7-H3/CD276

/
HY-P704335 HER2/CD340 Protein, Human (HEK293, mFc)
The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (HEK293, mFc) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293, with C-mFc labeled tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors CAR-T Related Proteins CD Antigens Receptor Proteins Enzymes & Regulators EGF Superfamily ErbB2/HER2 Stem Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Receptor Tyrosine Kinases Cytokine Receptors Protein Tyrosine Kinases EGFR/ErbB family

/
HY-P704456 FITC-Labeled CD276/B7-H3 (4Ig)/B7-H3b Protein, Human (HEK293, His)
CD276/B7-H3 protein can regulate T cell-mediated immune responses and act as a protective factor for tumor cells by inhibiting natural killer-mediated cell lysis. It also functions as a neuroblastoma cell marker, plays a role in acute and chronic transplant rejection, and modulates lymphocyte activity at mucosal surfaces. FITC-Labeled CD276/B7-H3 (4Ig)/B7-H3b Protein, Human (HEK293, His) is the recombinant human-derived FITC-Labeled CD276/B7-H3 protein, expressed by HEK293, with C-His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CAR-T Related Proteins CD Antigens Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins B7-H3 B7-H3/CD276

/
HY-P84637 CD276/B7H3 Antibody (YA4334)
CD276/B7H3 Antibody (YA4334) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD276/B7H3.

Host: Mouse; Reactivity: Human, Mouse, Rat, Rabbit, Monkey

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P810934 TGF beta 2 Antibody
TGF beta 2 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to TGF beta 2.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P811220 TGF beta 2/ TGFB2 Antibody
TGF beta 2/ TGFB2 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to TGF beta 2.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P85833 CD276/B7H3 Antibody (YA5525)
CD276/B7H3 Antibody (YA5525) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD276/B7H3.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P810816 TGF beta 2 Antibody (YA10059)
TGF beta 2 Antibody (YA10059) is a Mouse-derived and non-conjugated IgG1 Monoclonal antibody, targeting to TGF beta 2.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84637A CD276/B7H3 Antibody (YA4334)(PBS only)
CD276/B7H3 Antibody (YA4334) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD276/B7H3.

Host: Mouse; Reactivity: Human, Mouse, Rat, Rabbit, Monkey

Monoclonal Antibodies Primary Antibodies

/
HY-P84983 CD276/B7H3 Antibody (YA4675)
CD276/B7H3 Antibody (YA4675) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD276/B7H3.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Nanobodies Primary Antibodies

/
HY-P85087 CD276/B7H3 Antibody (YA4779)
CD276/B7H3 Antibody (YA4779) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD276/B7H3.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81534 CD276 Antibody (YA1279)
CD276 Antibody (YA1279) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD276.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81534A CD276 Antibody (YA1279)(PBS only)
CD276 Antibody (YA1279) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD276.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83319 B7H3/ICOSL Antibody (YA3064)
B7H3/ICOSL Antibody (YA3064) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to B7H3/ICOSL.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83319A B7H3/ICOSL Antibody (YA3064)(PBS only)
B7H3/ICOSL Antibody (YA3064) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to B7H3/ICOSL.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86719 C-erbB-2/HER2 Antibody (YA6411)
C-erbB-2/HER2 Antibody (YA6411) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to C-erbB-2/HER2.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P86719A C-erbB-2/HER2 Antibody (YA6411)(PBS only)
C-erbB-2/HER2 Antibody (YA6411) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to C-erbB-2/HER2.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P811097 CD213a2 Antibody
CD213a2 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to CD213a2.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/

Keywords

glioblastoma | CAR-T therapy | IL13Rα2 | EGFRvIII | B7-H3 | brain tumor microenvironment